Skip to main content
Premium Trial:

Request an Annual Quote

ChipDx Eyeing FDA Submission for Breast Cancer Relapse Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ChipDx today said that it plans to file for US regulatory approval of its test for breast cancer recurrence.

ChipDx Founder and Chief Scientific Officer Ryan van Laar told GenomeWeb Daily News that the company has received pre-IDE evaluations for one of BreastGeneDx's signatures from the US Food and Drug Administration's Center for Devices and Radiological Health and is looking for partners to "assist in pursuing the next stage of the assay validation/FDA submission process."

The firm, he said, also has received pre-IDE evaluation for one signature from FDA for its Cancer GeneDx test to detect cancer of unknown origin. ChipDx has also developed ColonGeneDx for predicting recurrence and survival of patients with colon cancer, which is available for research-use only.

Current commercialization efforts are focused on the breast cancer test. The 200 gene signature test is for the prediction of breast cancer relapse and was designed to be used on the Affymetrix GeneChip microarray system. It is currently available online for research-use only.

The New York-based molecular diagnostics firm said that a recent study published in the Journal of Molecular Diagnostics that analyzed whole-genome profiles of 477 breast cancer patients suggested BreastGeneDx is "the strongest predictor of outcome in each validation series, compared to other methods of predicting breast cancer prognosis."

In untreated node-negative patients the test achieved 88 percent sensitivity and 44 percent specificity for 10-year recurrence-free survival. Positive and negative predictive values were 32 percent and 92 percent, respectively, ChipDx said.

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.